Gastrointestinal stromal tumours: Clinical overview, surgery and recent advances in imatinib mesylate therapy

European Journal of Surgical Oncology

Volumn 33, Issue 8, 2007, Pages 942-950

  Samelis, G F ^a   Ekmektzoglou, K A ^b   Zografos, G C ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Gastrointestinal stromal tumour; GIST; Imatinib; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE; IMATINIB; MITOXANTRONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ADJUVANT THERAPY; ANEMIA; CANCER SURVIVAL; CARCINOGENESIS; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; HEMOPERITONEUM; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; MEDLINE; MESENTERY TUMOR; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 34548782293     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.11.025     Document Type: Review

References (78)

1. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103 (2005) 821-829
2. Mazur M.T., and Clark H.B. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7 (1983) 507-519
3. Perez E.A., Livingstone A.S., Franceschi D., et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 202 (2006) 623-629
4. Kindblom L.G., Remotti H.E., Aldenborg F., and Meis-Kindblom J.M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152 (1998) 1259-1269
5. Sircar K., Hewlett B.R., Huizinga J.D., Chorneyko K., Berezin I., and Riddell R.H. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 23 (1999) 377-389
6. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33 (2002) 459-465
7. Miettinen M., Lasota J., and Sobin L.H. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29 (2005) 52-68
8. Miettinen M., Kopczynski J., Makhlouf H.R., et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 27 (2003) 625-641
9. Tran T., Davila J.A., and El-Serag H.B. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 100 (2005) 162-168
10. Carney J.A., and Stratakis C.A. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 108 (2002) 132-139
11. Maertens O., Prenen H., Debiec-Rychter M., et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 15 (2006) 1015-1023
12. Li F.P., Fletcher J.A., Heinrich M.C., et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 23 (2005) 2735-2743
13. Davila R.E., and Faigel D.O. GI stromal tumors. Gastrointest Endosc 58 (2003) 80-88
14. Roberts P.J., and Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 38 Suppl. 5 (2002) S37-S38
15. Eisenberg B.L., and Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 11 (2004) 465-475
16. Lehnert T. Gastrointestinal sarcoma (GIST)-a review of surgical management. Ann Chir Gynaecol 87 (1998) 297-305
17. Blay J.Y., Bonvalot S., Casali P., et al. GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16 (2005) 566-578
18. Rothlin M., and Schob O. Laparoscopic wedge resection for benign gastric tumors. Surg Endosc 15 (2001) 893-895
19. Matsui H., Uyama I., Fujita J., Komori Y., Sugioka A., and Hasumi A. Gastrointestinal stromal tumor of the stomach successfully treated by laparoscopic proximal gastrectomy with jejunal interposition. Surg Laparosc Endosc Percutan Tech 10 (2000) 239-242
20. Cueto J., Vazquez-Frias J.A., Castaneda-Leeder P., Baquera-Heredia J., and Weber-Sanchez A. Laparoscopic-assisted resection of a bleeding gastrointestinal stromal tumor. JSLS 3 (1999) 225-228
21. Pierie J.P., Choudry U., Muzikansky A., Yeap B.Y., Souba W.W., and Ott M.J. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136 (2001) 383-389
22. Crosby J.A., Catton C.N., Davis A., et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 8 (2001) 50-59
23. DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., and Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
24. Burkill G.J., Badran M., Al-Muderis O., et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 226 (2003) 527-532
25. Kosmadakis N., Visvardis E.E., Kartsaklis P., et al. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness. Surg Oncol 14 (2005) 75-84
26. Moiz S.R., Ganesan B.H., and Lee T.D. Laparoendoscopic removal of a benign gastric stromal tumor at the cardia. JSLS 10 (2006) 117-121
27. Joensuu H., Fletcher C., Dimitrijevic S., Silberman S., Roberts P., and Demetri G. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 3 (2002) 655-664
28. Tornillo L., and Terracciano L.M. An update on molecular genetics of gastrointestinal stromal tumors. J Clin Pathol 59 (2006) 557-563
29. Miettinen M., Majidi M., and Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 38 Suppl. 5 (2002) S39-S51
30. Debiec-Rychter M., Wasag B., Stul M., et al. Gastrointestinal stromal tumors (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 202 (2004) 430-438
31. Sihto H., Franssila K., Tanner M., et al. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumors. Scand J Gastroenterol 41 (2006) 805-811
32. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
33. Wasag B., Debiec-Rychter M., Pauwels P., et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol 17 (2004) 889-894
34. van Oosterom A.T., Judson I., Verweij J., et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 358 (2001) 1421-1423
35. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
36. Van den Abbeele A.D., and Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 Suppl. 5 (2002) S60-S65
37. Glabbeke M.V., Verweij J., Casali P.G., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumors treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42 (2006) 2277-2285
38. Hogenauer C., Langner C., Lipp R.W., Hofler G., Krejs G.J., and Hinterleitner T.A. Complete remission of a metastatic gastrointestinal stromal tumor with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumor with exon 11 mutation. Eur J Gastroenterol Hepatol 15 (2003) 323-327
39. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
40. Chacon M., Roca E., Huertas E., Loria F.S., and Domenechini E. CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol 23 (2005) 1580-1582
41. Verweij J., Casali P., Zalcberg J., et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG, and AGITG. Proc Am Soc Clin Oncol 22 (2003) [Abstract 3272]
42. Benjamin R.S., Rankin C., Fletcher C., et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 22 (2003) [Abstract 3271]
43. Rankin C., von Mehren M., Blanke C., et al. Collaborating Investigators of the North American Sarcoma Intergroup. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 22 (2004) [Abstract 9005]
44. Zalcberg J., Verweij J., Casali P.G., et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD)-an international, intergroup study of the EORTC, ISG and AGITG. Proc Am Soc Clin Oncol 22 (2004) [Abstract 9004]
45. Debiec-Rychter M., Sciot R., Le Cesne A., et al. EORTC Soft Tissue and Bone Sarcoma Group; The Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 42 (2006) 1093-1103
46. Heinrich M.C., Shoemaker J.S., Corless C.L., et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). Proc Am Soc Clin Oncol 23 (2005) [Abstract 7]
47. Hong X., Choi H., and Loyer E.M. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 26 (2006) 481-495
48. Reddy M.P., Reddy P., and Lilien D.L. F-18 FDG PET imaging in gastrointestinal stromal tumor. Clin Nucl Med 28 (2003) 677-679
49. Sandrasegaran K., Rajesh A., Rushing D.A., Rydberg J., Akisik F.M., and Henley J.D. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol 15 (2005) 1407-1414
50. Lassau N., Lamuraglia M., Chami L., et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 187 (2006) 1267-1273
51. Eisenberg B.L., and von Mehren M. Pharmacotherapy of gastrointestinal stromal tumors. Expert Opin Pharmacother 4 (2003) 869-874
52. Bauer S., Hartmann J.T., de Wit M., et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117 (2005) 316-325
53. Melichar B., Voboril Z., Nozicka J., et al. Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy. Intern Med 44 (2005) 1163-1168
54. Bumming P., Andersson J., Meis-Kindblom J.M., et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumors (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 89 (2003) 460-464
55. Scaife C.L., Hunt K.K., Patel S.R., et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 186 (2003) 665-669
56. Hohenberg B.L., Bauer S., Schneider U., et al. Tumor resection following imatinib pretreatment in GI stromal tumors. Proc Am Soc Clin Oncol 22 (2003) [Abstract 3288]
57. Rutkowski P., Nowecki Z., Nyckowski P., et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93 (2006) 304-311
58. Gronchi A., Fiore M., Bertulli R., et al. Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 23 (2005) [Abstract 9038]
59. Bonvalot S., Eldweny H., Pechoux C.L., et al. Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era. Ann Surg Oncol 13 (2006) 1596-1603
60. Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24 (2006) 2325-2331
61. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
62. Wu P.C., Langerman A., Ryan C.W., Hart J., Swiger S., and Posner M.C. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 134 (2003) 656-665 discussion 665-6
63. Desai J., Shankar S., Heinrich M.C., et al. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. Proc Am Soc Clin Oncol 22 (2004) [Abstract 3010]
64. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
65. Debiec-Rychter M., Cools J., Dumez H., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128 (2005) 270-279
66. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 (2004) 3813-3825
67. Growney J.D., Clark J.J., Adelsperger J., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106 (2005) 721-724
68. Tamborini E., Gabanti E., Lagonigro M.S., et al. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient. Cancer Res 65 (2005) 1115 author reply 1115
69. van Oosterom A.T., Dumez H., Desai J., et al. Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. Proc Am Soc Clin Oncol 22 (2004) [Abstract 3002]
70. Demetri G.D., Desai J., Fletcher J.A., et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22 (2004) [Abstract 3001]
71. Evans T.R.J., Morgan J.A., van den Abbeele A.D., et al. Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. Proc Am Soc Clin Oncol 23 (2005) [Abstract 3034]
72. Duensing A., Joseph N.E., Medeiros F., et al. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 64 (2004) 5127-5131
73. van Glabbeke M., Verweij J., Casali P.G., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23 (2005) 5795-5804
74. Blay J.Y., Berthaud P., Perol D., et al. Continuous vs. intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. Proc Am Soc Clin Oncol 22 (2004) [Abstract 9006]
75. Le Cesne A., Perol D., Ray-Coquard I., et al. Interruption of imatinib (IM) in GIST patients with advanced disease: Updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. Proc Am Soc Clin Oncol 23 (2005) [Abstract 9031]
76. Manning W.C., Bello C.L., Deprimo S.E., et al. Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant stromal tumors. Proc Am Soc Clin Oncol 22 (2003) [Abstract 768]
77. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
78. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 368 (2006) 1303-1304